OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0526

Surgical Dressings (Wound Care Supplies)

Customize your policy alerts

Sign up for Aetna Policy 0526 alerts

Get alerted when Policy 0526 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity, limitations, and coverage criteria for surgical dressings and wound care supplies for Aetna members, including permitted frequencies, quantities, and product-specific guidance for home and provider-dispensed supplies.

Policy Summary

PayerAetna

PolicySurgical Dressings (Wound Care Supplies)

Policy CodePolicy 0526

Change TypeNo material change

Effective DateJul 3, 2001

Last ReviewJul 20, 2023

Next Review DateMay 23, 2024

Key ActionDocument medical necessity to justify quantities beyond a one-month supply when dispensing wound dressings.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

07/20/2023Policy last reviewed

~20+HCPCS codes listed

up to 3/weekCommon max frequency (composite/hydrocolloid/film)

up to 1/dayCommon max frequency (alginate/hydrogel/gauze)

1 monthMaximum supply without extra documentation

Coverage Criteria

inv-01: General medical necessity and supply quantity

Covered when ALL of the following are met

General: Surgical wound care supplies are medically necessary when prescribed by a physician and tailored to the individual member's wound needs; no more than a 1-month supply is considered medically necessary at one time unless documentation supports greater quantities.1-month supply

Suppliers expected to monitor actual utilization and adjust quantities

inv-02: Individual product coverage criteria

Product-specific coverage rules (each set applies when that product is used for indicated wound type/exudate level)

Alginate / Fiber gelling: Medically necessary for moderately to highly exudative full-thickness wounds (e.g., stage III or IV); up to 1 dressing change per day; one wound cover sheet approximately the size of the wound or up to 2 units of filler (1 unit = 6 inches of alginate/fiber rope) per dressing change unless more is documented.

Policy Summary

PayerAetna

PolicySurgical Dressings (Wound Care Supplies)

Policy CodePolicy 0526

Change TypeNo material change

Effective DateJul 3, 2001

Last ReviewJul 20, 2023

Next Review DateMay 23, 2024

Key ActionDocument medical necessity to justify quantities beyond a one-month supply when dispensing wound dressings.

SourceLink

On This Page

inv-03: Compatibility and change-frequency guidance

Secondary/primary dressing compatibility: Composite, foam, hydrocolloid wound covers and transparent film are intended for less-than-daily changes and should not be used with primary dressings that require more frequent changes; changes greater than once every other day for these dressings are not considered medically necessary unless clinically justified.<= once every other day

Avoid combinations that necessitate frequent changes (e.g., specialty absorptive dressing over non-impregnated gauze)

inv-04: Experimental / investigational (examples)

The following are considered experimental/investigational (not covered) due to insufficient evidence

Clinical situations of no proven benefit: First-degree burns, stage I pressure ulcers, routine venipuncture/arterial puncture sites (except indwelling catheter sites), drainage from cutaneous fistula not caused by surgery, and traumatic wounds not requiring surgical closure or debridement (e.g., skin tears, abrasions).

Specific experimental dressings: Amino acid dressings for chronic wounds; DACC-coated dressings for surgical site infection; ibuprofen foam dressings for painful venous leg ulcers; OxyBand wound dressing.

These items are considered experimental/investigational due to insufficient evidence

inv-05: General coverage (diagnosis and code contingent)

Covered when selection criteria are met for listed diagnoses and HCPCS codes

Coverage preconditions: The ICD-10 diagnosis must fall within the covered ranges (for example, pressure ulcers stage III or IV, non-pressure chronic ulcers stage III or IV, appropriate second- or third-degree burn codes, persistent postprocedural fistula, and open wounds) and the HCPCS/CPT code billed must not be listed as 'not covered under surgical dressings benefit'.

Selection criteria for specific codes/diagnoses must be documented in the medical record

inv-06: Evidence-summary coverage considerations

Summary of coverage-relevant clinical findings from cited evidence (useful for determining medical necessity or utilization management):

Tissue adhesives vs sutures: Randomized evidence indicates sutures are significantly better than tissue adhesives for minimizing dehiscence; tissue adhesives may be quicker to apply but have higher dehiscence risk.

Consider sutures when minimizing dehiscence is a priority

Dressings and SSI prevention: Systematic reviews (including Cochrane) found uncertain or very low-certainty evidence that any specific dressing (e.g., film, hydrocolloid, silver-containing) reduces surgical site infection compared with basic contact dressings or no dressing.

Dressing choice may be based on cost and patient preference

Silver-containing dressings: Meta-analyses did not find clear evidence that silver-containing dressings reduce SSIs compared with silver-free dressings; the quality of evidence is very low.

Further high-quality studies are needed

DACC-coated dressings: Limited but preliminary evidence exists for DACC-coated dressings reducing postoperative SSI and bacterial load; evidence remains insufficient and limited.

Consider documenting rationale when using these products

NPWT for severe open lower-limb fractures: A large multicenter RCT (n=460) found no statistically significant improvement in disability, deep infection rates, or quality of life at 12 months for NPWT versus standard dressings in severe open lower-limb fractures.

Routine use of NPWT in this indication is not supported by the cited trial

OxyBand evidence: A small randomized study (17 completers) reported shorter time to healing and lower pain for OxyBand versus Xeroform at donor sites; findings are preliminary and require validation.

Treat OxyBand as limited/preliminary evidence when considering coverage

Chlorhexidine-impregnated dressings for CVCs: A meta-analysis of 12 RCTs (6,028 participants) reported reductions in catheter colonization and catheter-related bloodstream infection; CDC recommends chlorhexidine-impregnated dressings for short-term, non-tunneled adult CVCs when the product has FDA-cleared labeling for CRBSI reduction.

Supports coverage when product labeling and clinical indication align

Under Aetna’s standard traditional plans (Managed Choice POS, PPO, and indemnity), surgical dressings are covered only when prescribed by a physician and supplied by a home care agency in conjunction with covered home health services or when dispensed and used by a participating health care provider in conjunction with treatment. Supplies that do not require a prescription, are available over-the-counter, or are provided to the member as take-home supplies are not covered under traditional plans; benefit plan descriptions should be checked for specific plan variations.

Coding and Billing Codes

Covered CPT/HCPCS codes when criteria met (examples from list)mixedCovered

16020	Dressings and/or debridement of partial-thickness burns, initial or subsequent; small (less than 5% total body surface are).
16025	medium (eg, whole face or whole extremity, or 5 % to 10% total body surface area).
16030	large (eg, more than one extremity, or greater than 10% total body surface area).
96574	Debridement of premalignant hyperkeratotic lesion(s) (ie, targeted curettage, abrasion) followed with photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care.
97597	Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (eg, fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application(s), wound assessment, use of a whirlpool, when performed and instruction(s) for ongoing care, per session total wound(s) surface area; first 20 sq cm or less.
97598	each additional 20 sq cm, or part thereof (list separatley in addition to code for primary procedure).
97602	Removal of devitalized tissue from wound(s), non-selective debridement, without anesthesia (eg, wet-to-moist dressings, enzymatic, abrasion), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session.
A4216	Sterile water, saline and/or dextrose, dilute flush, 10 ml [not covered under surgical dressings benefit]
A4450	Tape, non-waterproof, per 18 sq. in.
A4452	Tape, waterproof, per 18 sq. in.

1–10 of 30

1/3

Not covered / excluded itemsHCPCSNot Covered

A4216	Sterile water, saline and/or dextrose, dilute flush, 10 ml [not covered under surgical dressings benefit]
A4217	Sterile water/saline, 500 ml [not covered under surgical dressings benefit]
A6210	Foam dressing (ibuprofen foam dressings for painful venous leg ulcers) [not covered]

Listed HCPCS codes and descriptions (partial)HCPCS

A4217	Sterile water/saline, 500 ml [not covered under surgical dressings benefit]
A4450	Tape, non-waterproof, per 18 sq. in.
A4452	Tape, waterproof, per 18 sq. in.
A4649	Surgical supply; miscellaneous.
A6025	Gel sheet for dermal or epidermal application (e.g., silicone, hydrogel, other), each
A6154	Wound pouch, each
A6196-A6199	Alginate or other fiber gelling dressing
A6200-A6205	Composite dressing
A6206-A6208	Contact layer
A6209-A6215	Foam dressing [not covered for ibuprofen foam dressings for painful venous leg ulcers]

1–10 of 18

1/2

Additional HCPCS codes and exceptionsHCPCS

A6402-A6404	Gauze, non-impregnated, sterile
A6441	Padding bandage, nonelastic, nonwoven/nonknitted, width greater than or equal to 3 in. and less than 5 in., per yd.
A6442-A6447	Conforming bandage, nonelastic
A6448-A6452	Light, moderate, and high compression bandage, elastic
A6453-A6455	Self-adherent bandage, elastic
A6456	Zinc paste impregnated bandage, nonelastic, knitted/woven, width greater than or equal to 3 in., and less than 5 in., per yd.
A6460-A6461	Synthetic resorbable wound dressing, sterile, pad without adhesive border, each dressing
C1765	Adhesion barrier [not covered under surgical dressings benefit]
A4364	Adhesive, liquid or equal, any type, per oz. [not covered as an alternative to sutures in wound closure]
A4550	Surgical trays [not covered for provision or surgical dressings]

NPWT and related codes; collagen and other related codesHCPCS|CPT

A6550	Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories.
A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each.
E2402	Negative pressure wound therapy electrical pump, stationary or portable.
K0743	Suction pump, home model, portable, for use on wounds.
K0744	Absorptive wound dressing for use with suction pump, home model, portable, pad size 16 sq in or less.
K0745	Absorptive wound dressing for use with suction pump, home model, portable, pad size more than 16 sq in but less than or equal to 48 sq in.
K0746	Absorptive wound dressing for use with suction pump, home model, portable, pad size greater than 48 sq in.
A6010-A6011	Collagen based wound filler.
A6021-A6024	Collagen dressing.
A6457	Tubular dressing with or without elastic, any width, per linear yard.

1–10 of 11

1/2

HCPCS modifiersModifier

HCPCS Modifier A1-A9

Modifiers indicating the number of wounds per dressing (A1 = Dressing for one wound ... A9 = Dressing for nine or more wounds).

ICD-10 diagnosis codes (covered when selection criteria are met; not-covered lists)ICD-10

L89.003-L89.004, L89.013-L89.014, ...	Pressure ulcer [stage III or IV] (multiple specific codes listed).
L97.100-L97.929	Non-pressure chronic ulcer [stage III or IV].
T20.20x+ - T25.799+ (various)	Burns and corrosion codes (second or third degree) for multiple body regions.
T81.83x+	Persistent postprocedural fistula.
L08.9	Local infection of the skin and subcutaneous tissue, unspecified (listed as ICD-10 not covered for CPB indications).
L89.000 - L89.002, L89.009 - L89.012, ...	Pressure ulcer codes for stage I, II or unspecified (listed as not covered for CPB indications).
Numerous S-, S7-, S8- ranges	Open fractures and superficial injuries codes (many listed as not covered for CPB indications).

inv-23: Hydrogel filler maximum — 3 fluid ounces per wound per 30 days

LimitMaximum hydrogel filler billed without additional documentation: 3 fluid ounces per wound per 30 days.

Intended useHydrogel filler should be used only to line the surface of the wound; additional amounts used solely to fill a cavity are not considered medically necessary.

Combination useUse of both a hydrogel filler and a hydrogel cover on the same wound at the same time is of no proven benefit.

inv-24: Gradient compression wrap frequency — 1 per 6 months per leg

Frequency limitGradient compression (elastic) wrap replacement: 1 per 6 months per leg (usual medically necessary frequency unless more frequent replacement is documented).

Use caseElastic bandages are considered medically necessary when used as a secondary dressing to hold wound cover dressings in place; when used over an adhesive-border cover or secured by tape, they offer no proven benefit.

ReusabilityMost elastic bandages are reusable; no more than 1 replacement per week is considered medically necessary unless documented otherwise (note: this general guidance applies to elastic bandages; the gradient compression wrap specific limit above applies to replacement frequency).

inv-25: Pressure ulcer staging — Stage III or IV required for coverage in listed ranges

Coverage requirementPressure ulcers must be stage III or IV to meet the listed coverage ranges for the pressure-ulcer codes included in this policy.

ICD-10 mappingCovered ICD-10 ranges include specific pressure ulcer codes designated as stage III or IV (see CPT/HCPCS section for exact code ranges).

Not covered stagesStage I, II, or unspecified pressure ulcer codes are listed among not-covered indications for the surgical dressings benefit in this policy extract.

Provider Actions and Requirements

Denial Risk

Surgical Dressing Kits

When surgical dressing kits are provided, they will be considered not medically necessary because kits are non‑individualized packaging with fixed quantities or include materials not specifically prescribed for the member's wounds. Surgical dressings must be tailored to the member's individual needs; kits/trays that contain repetitive quantities or extra materials that are not each prescribed should not be billed as medically necessary.

Surgical dressing kits (standardized trays) are not medically necessary and may be denied.

Billing Rule

Quantity Limits and Denials for Excess Supplies

Quantities of non‑reusable items that exceed stated limits will be denied as not medically necessary. Examples include gradient compression wraps (limited to one per 6 months per leg) and other single-use items where policy-specific limits apply. Suppliers should monitor actual patient use and document medical necessity for quantities beyond routine limits (e.g., >1 month supply or more frequent dressing changes).

Gradient compression wrap: limited to one per 6 months per leg; quantities exceeding this will be denied.
General rule: no more than a 1‑month supply of dressings is medically necessary at one time unless documentation supports greater quantity.

Billing Rule

Billing Denials for Specific Codes and Diagnoses

Certain HCPCS codes and specific diagnoses may be denied when billed under the surgical dressings benefit. Verify that the code is covered for the intended indication and that selection criteria are met for covered ICD‑10 diagnoses. Billing for items that are explicitly listed as not covered may result in denial.

Examples of HCPCS not covered under the surgical dressings benefit: A4364, A4550 (surgical trays), A6550, A9272, E2402, K0743–K0746 (home suction pumps and related pads) — confirm benefit alignment before billing.
ICD‑10: pressure ulcers stage I–II or unspecified are not covered for the surgical dressings benefit; only stage III–IV and other specified covered codes apply when selection criteria are met.

Denial Risk

Denial Risk When Evidence Is Low or Uncertain

Because high‑quality evidence is limited or very low for many dressing comparisons (including some specialty, antimicrobial, or novel dressings), coverage may be limited or denied when requested products lack clinical superiority for the proposed indication. Providers should choose dressings based on clinical need, cost, and patient preference when evidence does not demonstrate clear benefit.

When evidence is very low or uncertain for a requested dressing compared with alternatives, denials are possible; document rationale for selecting a more costly or less well‑studied dressing.

Documentation Required

Alignment with FDA‑Cleared Indication for Chlorhexidine‑Impregnated Dressings

Use of chlorhexidine‑impregnated dressings for short‑term, non‑tunneled central venous catheters in adults should align with FDA‑cleared labeling that specifies an indication for reducing catheter‑related bloodstream infection (CRBSI/CABSI). When claiming CRBSI/CABSI prevention, ensure the product's FDA clearance supports that indication.

Align use with CDC recommendation and FDA‑cleared indication for short‑term, non‑tunneled CVCs in adults.
If the product is not FDA‑cleared for CRBSI/CABSI reduction, document the clinical rationale and supporting evidence if used.

Documentation Required

Documentation Supporting Medical Necessity for Quantities and Frequency

Documentation must support medical necessity for quantities or frequencies beyond standard limits (for example, more than a 1‑month supply, more frequent dressing changes than policy defaults, or billing multiple units of filler). Suppliers are expected to track actual use and adjust shipments accordingly.

Document the current wound status, exudate level, frequency of required dressing changes, and why standard quantity limits are insufficient.
Suppliers should have a mechanism to verify actual dressing use and adjust future provision.

Documentation Required

Documentation of Diagnosis and Selection Criteria

Selection criteria and clinical diagnosis must be documented for covered indications. For example, ICD‑10 codes for pressure ulcers, burns, persistent postprocedural fistula, and stage III/IV chronic ulcers require supporting clinical information to meet selection criteria for coverage.

Document the specific diagnosis (ICD‑10), wound stage (e.g., pressure ulcer stage III/IV), wound etiology, and clinical findings that meet the policy’s selection criteria.
Selection criteria must be met and clearly recorded in the medical record for the listed ICD‑10 codes to be considered covered.

Documentation Required

Documentation When Using Chlorhexidine‑Impregnated Dressings

When using chlorhexidine‑impregnated dressings for central venous catheters, document the indication, catheter type, and supporting evidence in the chart. The CDC recommends use for short‑term, non‑tunneled central venous catheters in adults when the dressing is FDA‑cleared for CRBSI/CABSI reduction.

Document catheter type (short‑term, non‑tunneled CVC), indication for chlorhexidine‑impregnated dressing, and cite the FDA‑cleared labeling or supporting RCT/meta‑analysis evidence.
If claiming CRBSI/CABSI prevention, include clinical rationale, dressing change frequency, and any relevant nursing care protocols.

Documentation Required

Required Clinical Documentation

Required clinical documentation should include the clinical indication for the dressing, wound characteristics (size, depth, stage, amount of exudate), intended dressing change frequency, and whether the dressing type is tailored to the wound. For chlorhexidine dressings over CVCs, document catheter type and indication.

Record wound measurements, wound stage (e.g., stage III/IV pressure ulcer), exudate level, presence of infection, and prior treatments tried.
Specify the dressing type, number of units dispensed, planned frequency of changes, and justification for any deviation from standard policy limits.

Documentation Required

Avoid Use of Secondary Dressings with Frequently‑Changed Primary Dressings

Avoid using secondary dressings that are designed for less frequent changes on top of primary dressings that require more frequent changes. For example, do not place composite, foam, hydrocolloid, or transparent film secondary dressings over primary dressings that need daily changes; such combinations are typically not medically necessary.

Do not use secondary dressings (composite, foam, hydrocolloid, transparent film) when the underlying primary dressing requires more frequent than the secondary's intended change interval.
Document rationale if such a combination is clinically required (e.g., initially highly exudative wounds), and re‑evaluate as wound status changes.

Note

Dressing Selection Preference When Evidence Is Lacking

When evidence does not show one postoperative dressing to be superior, selection may be based on cost and patient preference. Providers should document the clinical rationale for dressing choice when no clear evidence favoring one product exists.

Dressing selection preference: choose among clinically appropriate options based on cost, availability, and patient preference when high‑quality evidence of superiority is lacking.
Document the shared decision‑making or cost rationale when selecting a particular dressing.

Clinical Background and Evidence

Surgical dressings include primary and secondary dressings and wound fillers used to protect wounds, absorb exudate, maintain a moist environment, and assist debridement. Product selection should be based on wound depth, exudate level, and intended dressing change frequency; inappropriate combinations (for example, hydrating and absorptive dressings applied simultaneously) are generally not beneficial. Dressings designed for less-frequent changes (e.g., composite, foam, hydrocolloid, transparent film) should not be paired with primary dressings that require frequent changes.

inv-06 (cross-reference): Evidence-summary coverage considerations

Summary of clinical findings and evidence context (background):

Tissue adhesives vs sutures: Sutures reduce dehiscence more effectively than tissue adhesives; while adhesives may save time, clinicians should consider higher dehiscence risk when selecting closure method.

Evidence from systematic reviews and RCTs

Dressing comparisons and SSI: Cochrane and other systematic reviews (29 trials) found limited and low-quality evidence that specific dressings reduce surgical site infections; many trials are small and at unclear or high risk of bias.

Consider cost and patient preference in absence of clear benefit

Silver dressings: Meta-analyses of silver-containing dressings did not demonstrate reduced SSI rates versus controls; evidence quality rated very low.

Further high-quality studies needed

NPWT evidence for open fractures: A large RCT showed no benefit of NPWT over standard dressings for severe open lower-limb fractures in key clinical outcomes at 12 months.

Clinical reviewers should not assume routine benefit in this indication

OxyBand findings: Preliminary small RCT data suggest potential benefit in donor-site healing time and pain, but sample size is very small and findings require validation before broad adoption.

Treat as preliminary evidence for coverage decisions

Chlorhexidine-impregnated dressings for CVCs: Meta-analysis of 12 RCTs found reduced catheter colonization and CRBSI; CDC recommends use for short-term non-tunneled adult CVCs when product labeling specifies CRBSI reduction.

Coverage appropriate when clinical indication and FDA-cleared labeling align

Definitions and Terms

inv-45: Wound cover with adhesive border — definition / key features

DefinitionA wound cover with adhesive border is an integrated cover with a distinct adhesive border designed to adhere tightly to the skin; when used, additional overlying dressings are usually not needed and extra tape is usually not medically necessary.

Clinical roleConsidered medically necessary for wounds requiring less frequent dressing changes due to stronger adhesion compared with separate taping.

DocumentationReasons for use of additional tape or additional dressings when an adhesive-border cover is used should be documented.

inv-46: Alginate / fiber gelling dressing — definition and usage

DefinitionAlginate / fiber gelling dressings are covers or fillers for moderately to highly exudative full-thickness wounds (e.g., stage III or IV ulcers); fillers are used for wound cavities (1 unit = 6 inches of rope).

Change frequencyUp to 1 dressing change per day is considered medically necessary unless more frequent changes are documented.

LimitationsThey are of no proven benefit on dry wounds or wounds covered with eschar and are usually not considered medically necessary in combination with hydrogels.

inv-47: HCPCS modifier A1–A9 — modifiers indicating the number of wounds covered by a dressing

PurposeHCPCS modifiers A1–A9 indicate the number of wounds covered by a dressing when billing (A1 = dressing for one wound through A9 = dressing for nine or more wounds).

Billing applicationApply the appropriate A‑modifier to the dressing HCPCS code to reflect the number of wounds treated on the same date of service.

Codes referencedModifiers are listed alongside dressing HCPCS ranges (e.g., A6196–A6259) in the coding section of the policy for correct billing population mapping.

inv-48: Negative pressure wound therapy (NPWT) codes — E2402, K0743-K0746, A6550 relationships

Key codesE2402 = negative pressure wound therapy electrical pump; K0743–K0746 = home-model suction pumps and absorptive dressing pads by pad size; A6550 = wound care set for NPWT pump.

RelationshipsA6550 includes supplies/accessories for NPWT pumps; K0744–K0746 correspond to absorptive dressings for home-model suction pumps by pad size (<=16 sq in, >16–<=48 sq in, >48 sq in).

Prior auth notePrior authorization may be required for durable NPWT pumps and related home suction pump supplies (codes K0743–K0746, E2402).

inv-49: Stage I-IV pressure ulcers — brief overview (pointer to appendix)

OverviewPressure ulcers are staged I–IV; the appendix defines each stage and the policy references these stages when determining coverage.

PointerSee policy appendix 'Staging of Pressure Ulcers' for detailed stage definitions and mapping to ICD-10 codes used for coverage decisions.

Coverage implicationCoverage and allowable dressing types/frequencies depend on the ulcer stage (e.g., many advanced dressings indicated for stage III–IV).

inv-50: Negative pressure wound therapy (NPWT) — definition of therapy mechanism

MechanismNegative pressure wound therapy places an open-cell foam or gauze over the wound and connects it to a suction pump to create a partial vacuum that removes fluid and blood from the wound surface.

Intended effectThe partial vacuum reduces edema, removes exudate, and may promote wound edge approximation and granulation tissue formation.

Clinical noteA large RCT in severe open lower-limb fractures found no improvement in key outcomes for NPWT versus standard dressings in that specific indication; consider indication-specific evidence when requesting NPWT.

inv-51: Stage I pressure ulcer — definition

DefinitionStage I pressure ulcer: non-blanchable erythema of intact skin.

Coverage noteStage I ulcers are typically not within the advanced-dressing coverage ranges that require stage III–IV; verify ICD-10 coding and policy exclusions.

Appendix referenceSee the policy appendix for full staging table and code mapping used in coverage determinations.

inv-52: Stage II pressure ulcer — definition

DefinitionStage II pressure ulcer: partial-thickness skin loss involving epidermis and/or dermis.

Coverage noteHydrogel dressings are typically of no proven benefit for stage II ulcers unless documentation supports use; documentation must substantiate medical necessity for stage II use.

Appendix referenceRefer to the policy appendix for the complete stage definitions and code mapping for billing/coverage.

inv-53: Stage III pressure ulcer — definition

DefinitionStage III pressure ulcer: full-thickness skin loss involving damage or necrosis of subcutaneous tissue that may extend down to, but not through, underlying fascia.

Clinical implicationAlginate/fiber gelling dressings and many specialty absorptive dressings are considered medically necessary for moderately to highly exudative full-thickness wounds such as stage III ulcers.

Coding noteCovered ICD-10 pressure-ulcer code ranges include stage III codes; confirm stage-specific ICD-10 when billing for advanced dressings.

inv-54: Stage IV pressure ulcer — definition

DefinitionStage IV pressure ulcer: full-thickness skin loss with extensive destruction, tissue necrosis or damage to muscle, bone, or supporting structures.

Clinical implicationMany advanced dressings (alginate, specialty absorptive, NPWT when indicated) are intended for stage IV wounds given high exudate and tissue loss; coverage depends on meeting selection criteria.

DocumentationDocument the stage and clinical findings to support use of advanced dressings and any quantities/frequencies exceeding standard limits.

Surgical Dressings (Wound Care Supplies)

Sign up for Aetna Policy 0526 alerts

Coverage Criteria

Coding and Billing Codes

Provider Actions and Requirements

Clinical Background and Evidence

Definitions and Terms

Revision History